Literature DB >> 1711919

Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.

G Nicolò1, S Salvi, G Oliveri, L Borsi, P Castellani, L Zardi.   

Abstract

Tenascin (TN) and the oncofetal ED-B containing fibronectin isoform (B-FN) have been reported to be stromal markers of a number of malignancies. Here we report on studies of the distribution of TN and B-FN in normal adult tissues and in benign and malignant tumors, as well as on the levels of the B-FN mRNA in cultured fetal and non-fetal human fibroblasts originating from different tissues. B-FN has an extremely restricted distribution in normal adult tissues, is not expressed in benign tumors, but is greatly expressed in a high percentage of malignant tumors. On the contrary, human TN in normal adult tissues is less restricted than what has previously been reported and it is largely expressed in a number of both benign and malignant tumors. Moreover, we observed a great variability in the relative amount of B-FN mRNA among the 17 normal human fibroblast cell lines tested. We found very low levels in non-fetal skin fibroblasts and higher levels in fetal lung fibroblasts. We also found differences in the relative amounts of B-FN mRNA between fibroblast cell lines originating from the skin and the lung of the same subject.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1711919     DOI: 10.1016/0922-3371(90)90056-3

Source DB:  PubMed          Journal:  Cell Differ Dev        ISSN: 0922-3371


  8 in total

1.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

2.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

3.  Tenascin distribution in human brain tumours.

Authors:  P Castellani; A Dorcaratto; A Siri; L Zardi; G L Viale
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  Fibronectin synthesis by activated T lymphocytes: up-regulation of a surface-associated isoform with signalling function.

Authors:  C Wagner; A Bürger; M Radsak; S Blum; F Hug; G M Hänsch
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

Review 5.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

6.  Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer.

Authors:  Shanna A Arnold; Holli A Loomans; Tatiana Ketova; Claudia D Andl; Peter E Clark; Andries Zijlstra
Journal:  Clin Exp Metastasis       Date:  2015-10-11       Impact factor: 5.150

7.  Adaptation of the group A Streptococcus adhesin Scl1 to bind fibronectin type III repeats within wound-associated extracellular matrix: implications for cancer therapy.

Authors:  Dudley H McNitt; Soo Jeon Choi; Jessica L Allen; River A Hames; Scott A Weed; Livingston Van De Water; Rita Berisio; Slawomir Lukomski
Journal:  Mol Microbiol       Date:  2019-06-12       Impact factor: 3.501

8.  Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe.

Authors:  Jlenia Brunetti; Lorenzo Depau; Chiara Falciani; Mariangela Gentile; Elisabetta Mandarini; Giulia Riolo; Pietro Lupetti; Alessandro Pini; Luisa Bracci
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.